【摘要】 目的 观察二陈汤合三子养亲汤加减辅助治疗慢性阻塞性肺疾病急性加重期（AECOPD）的临床疗效。方法 将80例AECOPD痰浊阻肺证患者按照随机数字表法分为2组，对照组40例予对症支持综合性治疗，观察组40例在对照组治疗基础上予二陈汤合三子养亲汤加减治疗。2组均治疗1周。比较2组治疗前后中医证候评分、炎症因子[C反应蛋白（CRP）、降钙素原（PCT）]、血气指标[动脉血氧分压（PaO₂）、动脉血二氧化碳分压（PaCO₂）],并统计2组疗效及不良反应发生情况。结果 治疗期间观察组剔除脱落3例，对照组剔除脱落5例。观察组总有效率97.30%（36/37）,对照组总有效率77.14%（27/35）,观察组临床疗效优于对照组（P<0.05）。2组治疗后主要证候及次要证候评分均较本组治疗前降低（P<0.05）,且观察组治疗后均低于对照组（P<0.05）。2组治疗后CRP、PCT水平均较本组治疗前降低（P<0.05）,且观察组治疗后均低于对照组（P<0.05）。2组治疗后PaO₂均较本组治疗前升高（P<0.05）,PaCO₂均降低（P<0.05）,且观察组治疗后PaO₂高于对照组（P<0.05）,PaCO₂低于对照组（P<0.05）。2组治疗期间不良反应发生率比较差异无统计学意义（P>0.05）。结论 二陈汤合三子养亲汤加减辅助治疗AECOPD,抑炎效果好，患者血气指标显著改善，症状缓解，整体疗效提高，且安全性好。更多还原

【Abstract】 Objective To evaluate the efficacy of modified Erchen Decoction combined with Sanzi Yangqin Decoction for patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease（AECOPD） presenting with the phlegm-turbidity obstructing the lung pattern. Methods Eighty eligible AECOPD patients were randomized（random number table） into two groups: Control（n=40）, receiving standard symptomatic supportive care; and intervention（n=40）, receiving the same standard care plus oral modified Erchen Decoction combined with Sanzi Yangqin Decoction for 7 days. Outcomes assessed before and after treatment included traditional Chinese medicine（TCM） syndrome scores（major and minor symptoms）, inflammatory biomarkers（C-reactive protein [CRP], procalcitonin [PCT]）, and arterial blood gas parameters（partial pressure of oxygen [PaO₂], partial pressure of carbon dioxide [PaCO₂]）. Overall clinical efficacy and adverse events were also recorded. Results Three patients in the intervention group and five in the control group were excluded or lost during treatment, respectively. The total effective rate was significantly higher in the intervention group than in the control group（97.30% [36/37] vs. 77.14% [27/35]; P<0.05）. Both groups experienced significant reductions in TCM symptom scores and inflammatory markers（CRP, PCT） and improvements in arterial blood gases（increased PaO₂ and decreased PaCO₂） compared with baseline（all P<0.05）. Post-treatment TCM scores and inflammatory markers were significantly lower in the intervention group than in controls（P<0.05）. After treatment, the intervention group demonstrated higher PaO₂ and lower PaCO₂ than the control group（P<0.05）. Adverse event rates did not differ significantly between groups（P>0.05）. Conclusion In patients with phlegm-turbidity AECOPD, adjunctive treatment with modified Erchen Decoction combined with Sanzi Yangqin Decoction was associated with decreased inflammation, significant improvements in arterial blood gases and symptoms, and higher overall efficacy without increased adverse events.更多还原